HistoSonics Stock

Developing a non-invasive, autonomous robotic platform capable of destroying tissue at a sub-cellular level

Sign up today and learn more about HistoSonics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About HistoSonics Stock

HistoSonics, Inc. was created to advance the development of histotripsy, a science discovered and developed by leading scientists at the University of Michigan to provide improved therapies for patients. According to the company, its exclusive license to intellectual property, significant financial support, and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST)™, a novel beam therapy capable of destroying tissue at a sub-cellular level. HistoSonics’ team of specialists and industry leaders is based in Ann Arbor, Michigan.

Funding History

February 2010$14.0M
May 2014$0
December 2014$1.5M
September 2015$3.5M
March 2017$8.3M
July 2018$4.8M
April 2019$54.0M


VP of Regulatory & Clinical Affairs

Michael Daniel


Jon Freeman

VP of Research & Development

Joshua Stopek

VP of Operations

Daniel Bulver

President & CEO

Mike Blue

VP of Marketing

Josh King


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: